8.5 year-follow-up of combined heart-lung transplantation in a patient.
10.3969/j.issn.1672-7347.2013.02.018
- Author:
Baopeng SHANG
1
;
Jianguo HU
;
Xinmin ZHOU
;
Wei ZHANG
;
Xiaobo LIAO
;
Jianming LI
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Central South University, Changsha, China.
- Publication Type:Case Reports
- MeSH:
Eisenmenger Complex;
surgery;
Follow-Up Studies;
Graft Rejection;
Heart Septal Defects, Ventricular;
complications;
surgery;
Heart-Lung Transplantation;
methods;
Humans;
Hypertension, Pulmonary;
etiology;
surgery;
Immunosuppressive Agents;
therapeutic use;
Male;
Young Adult
- From:
Journal of Central South University(Medical Sciences)
2013;38(2):212-215
- CountryChina
- Language:Chinese
-
Abstract:
To summarize the case of combined heart-lung transplantation for a patient who survived for 8.5 years. On September 20, 2003, at Second Xiangya Hospital of Central South University, homologous heartlung transplantation was performed on a male patient who was diagnosed with cardiopulmonary failure secondary to congenital ventricular septal defect with severe pulmonary hypertension. Heart-lung allograft was preserved with 1500 mL modified St.Thomas solution and 3000 mL modified LPD solution. Postoperative immunosuppressive therapies included: methylprednisolone and human anti-lymphocyte globulin protein in the induction period; and combination of ciclosporin A, CellCept and prednisolone in the stable period. In 2007, the treatment was changed to CellCept mg, twice a day+FK506 4 mg, twice a day. The patient lived 8.5 years of normal life with cardiac function of NYHA I-II. Echocardiogram showed left ventricular ejection fraction of 61% to 74%. Heart-lung transplantation proved reliable therapy modality for terminal cardiopulmonary failure. Excellent donor organ preservation and proper perioperative treatment are key factors for long-term survival after heart-lung transplantation.
